Unwavering Tenacity to
Address Unmet Needs

Cardurion is dedicated to advancing novel mechanisms to create new treatments for cardiovascular disease, which remains the most significant cause of morbidity and mortality in our society.

To achieve this, we are focused on deep science, innovation, and collaboration as we work to create new treatments for heart failure and other cardiovascular diseases, and to bring transformative medicines to patients in areas of high unmet need.

Our innovative approach has resulted in two groundbreaking first-in-class clinical programs: a PDE9 (Phosphodiesterase-9) inhibitor and a CaMKII (Calcium–Calmodulin-Dependent Protein Kinase II) inhibitor.

See how Cardurion’s pipeline is expanding, positioning us for rapid growth across multiple indications. Please note that the safety and efficacy of the agents below are under investigation and have not been established.